Open and Recruiting
Clinical Trials

• 

  A First-in-Human Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

  • Sponsor

    Incyte Corporation

  • Trial ID

    NCT05836324

  • Study Details

    Study Details | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT05836324?intr=NCT05836324&rank=1

  • Cancer Type

    Advanced or Metastatic Solid Tumors

  • Status

    Recruiting

  Brief Summary

  To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

• 

  Phase 1/2, First-in-Human, Open-label, Multicenter, Study of DS-3939a in Subjects With Advanced Solid Tumors

  • Sponsor

    Daiichi Sankyo

  • Trial ID

    NCT05875168

  • Study Details

    Study Details | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT05875168?term=NCT05875168&rank=1

  • Cancer Type

    Advanced or Metastatic Solid Tumors

  • Status

    Recruiting

  Brief Summary

  DS-3939a is an antibody drug conjugate (ADC) being developed for the treatment of malignant tumors. This is a first-in-human, dose-escalating clinical study divided into 2 parts: the Dose Escalation Part (Part 1) and the Dose Expansion Part (Part 2). This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
  

• 

  A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Sponsor

    Boehringer Ingelheim

  • Trial ID

    NCT06806852

  • Study Details

    Study Details | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT06806852?term=NCT06806852&rank=1

  • Cancer Type

    Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Status

    Recruiting

  Brief Summary

  The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer.
  

• 

  A First-in-Human Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  • Sponsor

    Eli Lilly and Company

  • Trial ID

    NCT06586515

  • Study Details

    Study Details | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT06586515?term=LY3962673&rank=1

  • Cancer Type

    KRAS G12D-mutant advanced solid tumors

  • Status

    Recruiting

  Brief Summary

  The main purpose of this study is to assess safety & tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types.

• 

  A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

  • Sponsor

    AbbVie

  • Trial ID

    NCT06858813

  • Study Details

    Study Details | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT06858813?term=ABBV-324&rank=1

  • Cancer Type

    Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

  • Status

    Recruiting

  Brief Summary

  ABBV-324 is an investigational drug being developed for the treatment of HCC and LUSC. Study doctors put the participants in groups called arms. Each arm receives ABBV-324 alone (monotherapy) or a comparator drug, lenvatinib followed by a safety follow-up period.
  In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of ABBV-324 until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will receive ABBV-324, or a comparator of oral lenvatinib.

• 

  A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

  • Sponsor

    AbbVie

  • Trial ID

    NCT05005403

  • Study Details

    Study Details | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT05005403?intr=ABBV-514&rank=1

  • Cancer Type

    Advanced or Metastatic Solid Tumors

  • Status

    Recruiting

  Brief Summary

  The purpose of this study is to assess adverse events and pharmacokinetics of ABBV-514 as a monotherapy and in combination with Budigalimab. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of ABBV-514 will be explored. Each treatment arm receives a different dose of ABBV-514 in monotherapy and in combination with Budigalimab.

• 

  A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors

  This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.

  • Sponsor

    Chugai Pharma USA, Inc.

  • Trial ID

    NCT05907980

  • Study Details

    A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors

  • Cancer Type

    Advanced Solid Tumors

  • Status

    Preparing

  Brief Summary

  This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.

• 

  First-in-Human Study of STX-478 (LY4064809) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  https://clinicaltrials.gov/study/NCT05768139?term=STX-478&rank=2

  • Sponsor

    Eli Lilly / Scorpion Therapeutics, Inc.

  • Trial ID

    NCT05768139

  • Study Details

    First-in-Human Study of STX-478 (LY4064809) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT05768139?term=STX-478&rank=2

  • Cancer Type

    Advanced solid tumors with P13Ka mutations, HR+ breast cancer

  • Status

    Preparing

  Brief Summary

  This study is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer.

• 

  First-in-Human Phase 1 Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

  • Sponsor

    Boehringer Ingelheim

  • Trial ID

    NCT04958239

  • Study Details

    An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Study Url

    https://clinicaltrials.gov/study/NCT04958239

  • Cancer Type

    Advanced cancer (solid tumors) and head and neck cancer

  • Status

    Preparing

  Brief Summary

  This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of Part 1 of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. The goal of Part 2 is to find out whether BI 765179 in combination with a medicine called pembrolizumab helps people with advanced head and neck cancer.
  
  In Part 1, each participant is put into 1 of 2 groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. In Part 2, participants are also divided into 2 groups. 1 group gets a low dose of BI 765179 in combination with pembrolizumab and the other group gets a high dose of BI 765179 in combination with pembrolizumab. Participants receive the study treatment as infusions into a vein.
  
  BI 765179, ezabenlimab, and pembrolizumab are antibodies that may help the immune system fight cancer. In this study, BI 765179 is given to people for the first time.

• 

  A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of GSK5460025 in Patients with Advanced Solid Tumors

  • Sponsor

    GlaxoSmithKline（GSK）

For more information on phase one cancer
clinical trials,get in contact our team

Contact